APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anthrax Vaccines

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.

Selected research

Industry Growth & Trends

Global Anthrax Vaccines Industry Growth and Trends Forecast to 2032

Report ID 17396447011 January 2026120 pages

Choose your research edition.

Industry ResearchAnthrax Vaccines Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Anthrax Vaccines Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Anthrax Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anthrax Vaccines Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Anthrax Vaccines Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.

Global Anthrax Vaccines key players include Emergent BioSolutions, Merial, Merck, Zoetis, PharmAthene, etc. Global top five players hold a share about 70%.

North America is the largest market, with a share about 60%, followed by Latin America and Europe, having a total share about 20 percent.

Read the full market overview

In terms of product, Live Vaccines is the largest segment, with a share about 95%. And in terms of application, the largest application is Human Use, followed by Animal Use.

Report Scope

This report provides a structured, data-driven view of the global Anthrax Vaccines market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Anthrax Vaccines market size, estimates, and forecasts are presented in terms of sales volume (M Doses) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anthrax Vaccines market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anthrax Vaccines.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Anthrax Vaccines market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Anthrax Vaccines Market by Company

Emergent BioSolutions

Merial

Merck

Zoetis

Bayer Sanidad Animal

Colorado Serum

PharmAthene

Tiankang

Biogénesis-Bago

CAVAC

Rosenbusch

Agrovet

Vecol

CVCRI

IVPM

Prondil

CDV

Indian Immunologicals

Botswana Vaccine Institute

Ceva Santé Animale

Intervac

JOVAC

Anthrax Vaccines Segment by Type

Live Vaccines

Cell free PA Vaccines

Anthrax Vaccines Segment by Application

Human Use

Animal Use

Anthrax Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anthrax Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anthrax Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anthrax Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anthrax Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Anthrax Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Live Vaccines Table 2. Major Company of Cell free PA Vaccines Table 3. Global Anthrax Vaccines Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 5. Global Anthrax Vaccines Sales Market Share in Volume by Type (2021-2026) Table 6. Global Anthrax Vaccines Sales by Type (2021-2026) & (US$ Million) Table 7. Global Anthrax Vaccines Sales Market Share in Value by Type (2021-2026) Table 8. Global Anthrax Vaccines Price by Type (2021-2026) & (USD/Dose) Table 9. Global Anthrax Vaccines Sales by Type (2027-2032) & (M Doses) Table 10. Global Anthrax Vaccines Sales Market Share in Volume by Type (2027-2032) Table 11. Global Anthrax Vaccines Sales by Type (2027-2032) & (US$ Million) Table 12. Global Anthrax Vaccines Sales Market Share in Value by Type (2027-2032) Table 13. Global Anthrax Vaccines Price by Type (2027-2032) & (USD/Dose) Table 14. North America Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 15. North America Anthrax Vaccines Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 17. Europe Anthrax Vaccines Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 19. Asia-Pacific Anthrax Vaccines Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 21. Latin America Anthrax Vaccines Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 23. Middle East and Africa Anthrax Vaccines Sales by Type (2021-2026) & (US$ Million) Table 24. Anthrax Vaccines Industry Trends Table 25. Anthrax Vaccines Industry Drivers Table 26. Anthrax Vaccines Industry Opportunities and Challenges Table 27. Anthrax Vaccines Industry Restraints Table 28. Global Anthrax Vaccines Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Anthrax Vaccines Revenue Market Share by Company (2021-2026) Table 30. Global Anthrax Vaccines Sales by Company (2021-2026) & (M Doses) Table 31. Global Anthrax Vaccines Sales Share by Company (2021-2026) Table 32. Global Anthrax Vaccines Market Price by Company (2021-2026) & (USD/Dose) Table 33. Global Anthrax Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Anthrax Vaccines Major Company Production Sites and Headquarters Table 35. Global Anthrax Vaccines Company, Product Type & Application Table 36. Global Anthrax Vaccines Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Anthrax Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Anthrax Vaccines Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Anthrax Vaccines Sales by Region (2021-2026) & (M Doses) Table 41. Global Anthrax Vaccines Sales Market Share in Volume by Region (2021-2026) Table 42. Global Anthrax Vaccines Sales by Region (2021-2026) & (US$ Million) Table 43. Global Anthrax Vaccines Sales Market Share in Value by Region (2021-2026) Table 44. Global Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 45. Global Anthrax Vaccines Sales by Region (2027-2032) & (M Doses) Table 46. Global Anthrax Vaccines Sales Market Share in Volume by Region (2027-2032) Table 47. Global Anthrax Vaccines Sales by Region (2027-2032) & (US$ Million) Table 48. Global Anthrax Vaccines Sales Market Share in Value by Region (2027-2032) Table 49. Global Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2027-2032) Table 50. Global Anthrax Vaccines Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 52. Global Anthrax Vaccines Sales Market Share in Volume by Application (2021-2026) Table 53. Global Anthrax Vaccines Sales by Application (2021-2026) & (US$ Million) Table 54. Global Anthrax Vaccines Sales Market Share in Value by Application (2021-2026) Table 55. Global Anthrax Vaccines Price by Application (2021-2026) & (USD/Dose) Table 56. Global Anthrax Vaccines Sales by Application (2027-2032) & (M Doses) Table 57. Global Anthrax Vaccines Sales Market Share in Volume by Application (2027-2032) Table 58. Global Anthrax Vaccines Sales by Application (2027-2032) & (US$ Million) Table 59. Global Anthrax Vaccines Sales Market Share in Value by Application (2027-2032) Table 60. Global Anthrax Vaccines Price by Application (2027-2032) & (USD/Dose) Table 61. North America Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 62. North America Anthrax Vaccines Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 64. Europe Anthrax Vaccines Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 66. Asia-Pacific Anthrax Vaccines Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 68. Latin America Anthrax Vaccines Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 70. Middle East and Africa Anthrax Vaccines Sales by Application (2021-2026) & (US$ Million) Table 71. Emergent BioSolutions Company Information Table 72. Emergent BioSolutions Business Overview Table 73. Emergent BioSolutions Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 74. Emergent BioSolutions Anthrax Vaccines Product Portfolio Table 75. Emergent BioSolutions Recent Development Table 76. Merial Company Information Table 77. Merial Business Overview Table 78. Merial Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 79. Merial Anthrax Vaccines Product Portfolio Table 80. Merial Recent Development Table 81. Merck Company Information Table 82. Merck Business Overview Table 83. Merck Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 84. Merck Anthrax Vaccines Product Portfolio Table 85. Merck Recent Development Table 86. Zoetis Company Information Table 87. Zoetis Business Overview Table 88. Zoetis Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 89. Zoetis Anthrax Vaccines Product Portfolio Table 90. Zoetis Recent Development Table 91. Bayer Sanidad Animal Company Information Table 92. Bayer Sanidad Animal Business Overview Table 93. Bayer Sanidad Animal Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 94. Bayer Sanidad Animal Anthrax Vaccines Product Portfolio Table 95. Bayer Sanidad Animal Recent Development Table 96. Colorado Serum Company Information Table 97. Colorado Serum Business Overview Table 98. Colorado Serum Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 99. Colorado Serum Anthrax Vaccines Product Portfolio Table 100. Colorado Serum Recent Development Table 101. PharmAthene Company Information Table 102. PharmAthene Business Overview Table 103. PharmAthene Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 104. PharmAthene Anthrax Vaccines Product Portfolio Table 105. PharmAthene Recent Development Table 106. Tiankang Company Information Table 107. Tiankang Business Overview Table 108. Tiankang Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 109. Tiankang Anthrax Vaccines Product Portfolio Table 110. Tiankang Recent Development Table 111. Biogénesis-Bago Company Information Table 112. Biogénesis-Bago Business Overview Table 113. Biogénesis-Bago Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 114. Biogénesis-Bago Anthrax Vaccines Product Portfolio Table 115. Biogénesis-Bago Recent Development Table 116. CAVAC Company Information Table 117. CAVAC Business Overview Table 118. CAVAC Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 119. CAVAC Anthrax Vaccines Product Portfolio Table 120. CAVAC Recent Development Table 121. Rosenbusch Company Information Table 122. Rosenbusch Business Overview Table 123. Rosenbusch Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 124. Rosenbusch Anthrax Vaccines Product Portfolio Table 125. Rosenbusch Recent Development Table 126. Agrovet Company Information Table 127. Agrovet Business Overview Table 128. Agrovet Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 129. Agrovet Anthrax Vaccines Product Portfolio Table 130. Agrovet Recent Development Table 131. Vecol Company Information Table 132. Vecol Business Overview Table 133. Vecol Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 134. Vecol Anthrax Vaccines Product Portfolio Table 135. Vecol Recent Development Table 136. CVCRI Company Information Table 137. CVCRI Business Overview Table 138. CVCRI Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 139. CVCRI Anthrax Vaccines Product Portfolio Table 140. CVCRI Recent Development Table 141. IVPM Company Information Table 142. IVPM Business Overview Table 143. IVPM Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 144. IVPM Anthrax Vaccines Product Portfolio Table 145. IVPM Recent Development Table 146. Prondil Company Information Table 147. Prondil Business Overview Table 148. Prondil Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 149. Prondil Anthrax Vaccines Product Portfolio Table 150. Prondil Recent Development Table 151. CDV Company Information Table 152. CDV Business Overview Table 153. CDV Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 154. CDV Anthrax Vaccines Product Portfolio Table 155. CDV Recent Development Table 156. Indian Immunologicals Company Information Table 157. Indian Immunologicals Business Overview Table 158. Indian Immunologicals Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 159. Indian Immunologicals Anthrax Vaccines Product Portfolio Table 160. Indian Immunologicals Recent Development Table 161. Botswana Vaccine Institute Company Information Table 162. Botswana Vaccine Institute Business Overview Table 163. Botswana Vaccine Institute Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 164. Botswana Vaccine Institute Anthrax Vaccines Product Portfolio Table 165. Botswana Vaccine Institute Recent Development Table 166. Ceva Santé Animale Company Information Table 167. Ceva Santé Animale Business Overview Table 168. Ceva Santé Animale Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 169. Ceva Santé Animale Anthrax Vaccines Product Portfolio Table 170. Ceva Santé Animale Recent Development Table 171. Intervac Company Information Table 172. Intervac Business Overview Table 173. Intervac Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 174. Intervac Anthrax Vaccines Product Portfolio Table 175. Intervac Recent Development Table 176. JOVAC Company Information Table 177. JOVAC Business Overview Table 178. JOVAC Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 179. JOVAC Anthrax Vaccines Product Portfolio Table 180. JOVAC Recent Development Table 181. North America Anthrax Vaccines Market Size Growth Rate (CAGR) by Country (M Doses): 2021 VS 2025 VS 2032 Table 182. North America Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 183. North America Anthrax Vaccines Sales Market Share by Country (2021-2026) Table 184. North America Anthrax Vaccines Sales Forecast by Country (2027-2032) & (M Doses) Table 185. North America Anthrax Vaccines Sales Market Share Forecast by Country (2027-2032) Table 186. North America Anthrax Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. North America Anthrax Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 188. North America Anthrax Vaccines Market Share by Country (2021-2026) Table 189. North America Anthrax Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. North America Anthrax Vaccines Market Share Forecast by Country (2027-2032) Table 191. Europe Anthrax Vaccines Market Size Growth Rate (CAGR) by Country (M Doses): 2021 VS 2025 VS 2032 Table 192. Europe Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 193. Europe Anthrax Vaccines Sales Market Share by Country (2021-2026) Table 194. Europe Anthrax Vaccines Sales Forecast by Country (2027-2032) & (M Doses) Table 195. Europe Anthrax Vaccines Sales Market Share Forecast by Country (2027-2032) Table 196. Europe Anthrax Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 197. Europe Anthrax Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 198. Europe Anthrax Vaccines Market Share by Country (2021-2026) Table 199. Europe Anthrax Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 200. Europe Anthrax Vaccines Market Share Forecast by Country (2027-2032) Table 201. Asia-Pacific Anthrax Vaccines Market Size Growth Rate (CAGR) by Country (M Doses): 2021 VS 2025 VS 2032 Table 202. Asia-Pacific Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 203. Asia-Pacific Anthrax Vaccines Sales Market Share by Country (2021-2026) Table 204. Asia-Pacific Anthrax Vaccines Sales Forecast by Country (2027-2032) & (M Doses) Table 205. Asia-Pacific Anthrax Vaccines Sales Market Share Forecast by Country (2027-2032) Table 206. Asia-Pacific Anthrax Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 207. Asia-Pacific Anthrax Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 208. Asia-Pacific Anthrax Vaccines Market Share by Country (2021-2026) Table 209. Asia-Pacific Anthrax Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 210. Asia-Pacific Anthrax Vaccines Market Share Forecast by Country (2027-2032) Table 211. Latin America Anthrax Vaccines Market Size Growth Rate (CAGR) by Country (M Doses): 2021 VS 2025 VS 2032 Table 212. Latin America Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 213. Latin America Anthrax Vaccines Sales Market Share by Country (2021-2026) Table 214. Latin America Anthrax Vaccines Sales Forecast by Country (2027-2032) & (M Doses) Table 215. Latin America Anthrax Vaccines Sales Market Share Forecast by Country (2027-2032) Table 216. Latin America Anthrax Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 217. Latin America Anthrax Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 218. Latin America Anthrax Vaccines Market Share by Country (2021-2026) Table 219. Latin America Anthrax Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 220. Latin America Anthrax Vaccines Market Share Forecast by Country (2027-2032) Table 221. Middle East and Africa Anthrax Vaccines Market Size Growth Rate (CAGR) by Country (M Doses): 2021 VS 2025 VS 2032 Table 222. Middle East and Africa Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 223. Middle East and Africa Anthrax Vaccines Sales Market Share by Country (2021-2026) Table 224. Middle East and Africa Anthrax Vaccines Sales Forecast by Country (2027-2032) & (M Doses) Table 225. Middle East and Africa Anthrax Vaccines Sales Market Share Forecast by Country (2027-2032) Table 226. Middle East and Africa Anthrax Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 227. Middle East and Africa Anthrax Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 228. Middle East and Africa Anthrax Vaccines Market Share by Country (2021-2026) Table 229. Middle East and Africa Anthrax Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 230. Middle East and Africa Anthrax Vaccines Market Share Forecast by Country (2027-2032) Table 231. Key Raw Materials Table 232. Raw Materials Key Suppliers Table 233. Anthrax Vaccines Distributors List Table 234. Anthrax Vaccines Customers List Table 235. Research Programs/Design for This Report Table 236. Authors List of This Report Table 237. Secondary Sources Table 238. Primary Sources List of Figures Figure 1. Anthrax Vaccines Image Figure 2. Global Anthrax Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anthrax Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Anthrax Vaccines Sales (2021-2032) & (M Doses) Figure 5. Live Vaccines Image Figure 6. Global Live Vaccines Sales YoY Growth (2021-2032) & (M Doses) Figure 7. Cell free PA Vaccines Image Figure 8. Global Cell free PA Vaccines Sales YoY Growth (2021-2032) & (M Doses) Figure 9. Global Anthrax Vaccines Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Anthrax Vaccines Market Share by Type 2025 VS 2032 Figure 11. North America Anthrax Vaccines Sales Market Share in Volume by Type in 2025 Figure 12. North America Anthrax Vaccines Sales Market Share in Value by Type in 2025 Figure 13. Europe Anthrax Vaccines Sales Market Share in Volume by Type in 2025 Figure 14. Europe Anthrax Vaccines Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Anthrax Vaccines Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Anthrax Vaccines Sales Market Share in Value by Type in 2025 Figure 17. Latin America Anthrax Vaccines Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Anthrax Vaccines Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Anthrax Vaccines Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Anthrax Vaccines Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Anthrax Vaccines Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Human Use Image Figure 24. Global Human Use Sales YoY Growth (2021-2032) & (M Doses) Figure 25. Animal Use Image Figure 26. Global Animal Use Sales YoY Growth (2021-2032) & (M Doses) Figure 27. Global Anthrax Vaccines Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Anthrax Vaccines Market Share by Application 2025 VS 2032 Figure 29. North America Anthrax Vaccines Sales Market Share in Volume by Application in 2025 Figure 30. North America Anthrax Vaccines Sales Market Share in Value by Application in 2025 Figure 31. Europe Anthrax Vaccines Sales Market Share in Volume by Application in 2025 Figure 32. Europe Anthrax Vaccines Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Anthrax Vaccines Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Anthrax Vaccines Sales Market Share in Value by Application in 2025 Figure 35. Latin America Anthrax Vaccines Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Anthrax Vaccines Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Anthrax Vaccines Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Anthrax Vaccines Sales Market Share in Value by Application in 2025 Figure 39. North America Anthrax Vaccines Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Figure 40. North America Anthrax Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Anthrax Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Anthrax Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Anthrax Vaccines Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Figure 44. Europe Anthrax Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Anthrax Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Anthrax Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Anthrax Vaccines Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Figure 48. Asia-Pacific Anthrax Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Anthrax Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Anthrax Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Anthrax Vaccines Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Figure 52. Latin America Anthrax Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Anthrax Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Anthrax Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Anthrax Vaccines Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Figure 56. Middle East and Africa Anthrax Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Anthrax Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Anthrax Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Anthrax Vaccines Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Anthrax Vaccines Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Live Vaccines
  • Cell free PA Vaccines
Applications
  • Human Use
  • Animal Use
Companies covered
  • Emergent BioSolutions
  • Merial
  • Merck
  • Zoetis
  • Bayer Sanidad Animal
  • Colorado Serum
  • PharmAthene
  • Tiankang
  • Biogénesis-Bago
  • CAVAC
  • Rosenbusch
  • Agrovet
  • Vecol
  • CVCRI
  • IVPM
  • Prondil
  • CDV
  • Indian Immunologicals
  • Botswana Vaccine Institute
  • Ceva Santé Animale
  • Intervac
  • JOVAC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anthrax Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Anthrax Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Anthrax Vaccines Market by Type
  6. 1.3.1 Live Vaccines
  7. 1.3.2 Cell free PA Vaccines
  8. 1.4 Global Anthrax Vaccines Market Size by Type
  9. 1.4.1 Global Anthrax Vaccines Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Anthrax Vaccines Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Anthrax Vaccines Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Anthrax Vaccines Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Anthrax Vaccines Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Anthrax Vaccines Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Anthrax Vaccines Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Anthrax Vaccines Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Anthrax Vaccines Industry Trends
  2. 2.2 Anthrax Vaccines Industry Drivers
  3. 2.3 Anthrax Vaccines Industry Opportunities and Challenges
  4. 2.4 Anthrax Vaccines Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Anthrax Vaccines Revenue (2021-2026)
  2. 3.2 Global Top Players by Anthrax Vaccines Sales (2021-2026)
  3. 3.3 Global Top Players by Anthrax Vaccines Price (2021-2026)
  4. 3.4 Global Anthrax Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anthrax Vaccines Major Company Production Sites & Headquarters
  6. 3.6 Global Anthrax Vaccines Company, Product Type & Application
  7. 3.7 Global Anthrax Vaccines Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anthrax Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anthrax Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anthrax Vaccines Tier 1, Tier 2, and Tier 3
4 Anthrax Vaccines Regional Status and Outlook
  1. 4.1 Global Anthrax Vaccines Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Anthrax Vaccines Historic Market Size by Region
  3. 4.2.1 Global Anthrax Vaccines Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Anthrax Vaccines Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Anthrax Vaccines Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Anthrax Vaccines Forecasted Market Size by Region
  7. 4.3.1 Global Anthrax Vaccines Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Anthrax Vaccines Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Anthrax Vaccines Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Anthrax Vaccines by Application
  1. 5.1 Anthrax Vaccines Market by Application
  2. 5.1.1 Human Use
  3. 5.1.2 Animal Use
  4. 5.2 Global Anthrax Vaccines Market Size by Application
  5. 5.2.1 Global Anthrax Vaccines Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Anthrax Vaccines Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Anthrax Vaccines Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Anthrax Vaccines Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Anthrax Vaccines Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Anthrax Vaccines Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Anthrax Vaccines Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Anthrax Vaccines Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Emergent BioSolutions
  2. 6.1.1 Emergent BioSolutions Company Information
  3. 6.1.2 Emergent BioSolutions Business Overview
  4. 6.1.3 Emergent BioSolutions Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Emergent BioSolutions Anthrax Vaccines Product Portfolio
  6. 6.1.5 Emergent BioSolutions Recent Developments
  7. 6.2 Merial
  8. 6.2.1 Merial Company Information
  9. 6.2.2 Merial Business Overview
  10. 6.2.3 Merial Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Merial Anthrax Vaccines Product Portfolio
  12. 6.2.5 Merial Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck Anthrax Vaccines Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Zoetis
  20. 6.4.1 Zoetis Company Information
  21. 6.4.2 Zoetis Business Overview
  22. 6.4.3 Zoetis Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Zoetis Anthrax Vaccines Product Portfolio
  24. 6.4.5 Zoetis Recent Developments
  25. 6.5 Bayer Sanidad Animal
  26. 6.5.1 Bayer Sanidad Animal Company Information
  27. 6.5.2 Bayer Sanidad Animal Business Overview
  28. 6.5.3 Bayer Sanidad Animal Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Bayer Sanidad Animal Anthrax Vaccines Product Portfolio
  30. 6.5.5 Bayer Sanidad Animal Recent Developments
  31. 6.6 Colorado Serum
  32. 6.6.1 Colorado Serum Company Information
  33. 6.6.2 Colorado Serum Business Overview
  34. 6.6.3 Colorado Serum Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Colorado Serum Anthrax Vaccines Product Portfolio
  36. 6.6.5 Colorado Serum Recent Developments
  37. 6.7 PharmAthene
  38. 6.7.1 PharmAthene Company Information
  39. 6.7.2 PharmAthene Business Overview
  40. 6.7.3 PharmAthene Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 PharmAthene Anthrax Vaccines Product Portfolio
  42. 6.7.5 PharmAthene Recent Developments
  43. 6.8 Tiankang
  44. 6.8.1 Tiankang Company Information
  45. 6.8.2 Tiankang Business Overview
  46. 6.8.3 Tiankang Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Tiankang Anthrax Vaccines Product Portfolio
  48. 6.8.5 Tiankang Recent Developments
  49. 6.9 Biogénesis-Bago
  50. 6.9.1 Biogénesis-Bago Company Information
  51. 6.9.2 Biogénesis-Bago Business Overview
  52. 6.9.3 Biogénesis-Bago Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Biogénesis-Bago Anthrax Vaccines Product Portfolio
  54. 6.9.5 Biogénesis-Bago Recent Developments
  55. 6.10 CAVAC
  56. 6.10.1 CAVAC Company Information
  57. 6.10.2 CAVAC Business Overview
  58. 6.10.3 CAVAC Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 CAVAC Anthrax Vaccines Product Portfolio
  60. 6.10.5 CAVAC Recent Developments
  61. 6.11 Rosenbusch
  62. 6.11.1 Rosenbusch Company Information
  63. 6.11.2 Rosenbusch Business Overview
  64. 6.11.3 Rosenbusch Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Rosenbusch Anthrax Vaccines Product Portfolio
  66. 6.11.5 Rosenbusch Recent Developments
  67. 6.12 Agrovet
  68. 6.12.1 Agrovet Company Information
  69. 6.12.2 Agrovet Business Overview
  70. 6.12.3 Agrovet Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Agrovet Anthrax Vaccines Product Portfolio
  72. 6.12.5 Agrovet Recent Developments
  73. 6.13 Vecol
  74. 6.13.1 Vecol Company Information
  75. 6.13.2 Vecol Business Overview
  76. 6.13.3 Vecol Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Vecol Anthrax Vaccines Product Portfolio
  78. 6.13.5 Vecol Recent Developments
  79. 6.14 CVCRI
  80. 6.14.1 CVCRI Company Information
  81. 6.14.2 CVCRI Business Overview
  82. 6.14.3 CVCRI Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 CVCRI Anthrax Vaccines Product Portfolio
  84. 6.14.5 CVCRI Recent Developments
  85. 6.15 IVPM
  86. 6.15.1 IVPM Company Information
  87. 6.15.2 IVPM Business Overview
  88. 6.15.3 IVPM Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 IVPM Anthrax Vaccines Product Portfolio
  90. 6.15.5 IVPM Recent Developments
  91. 6.16 Prondil
  92. 6.16.1 Prondil Company Information
  93. 6.16.2 Prondil Business Overview
  94. 6.16.3 Prondil Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Prondil Anthrax Vaccines Product Portfolio
  96. 6.16.5 Prondil Recent Developments
  97. 6.17 CDV
  98. 6.17.1 CDV Company Information
  99. 6.17.2 CDV Business Overview
  100. 6.17.3 CDV Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 CDV Anthrax Vaccines Product Portfolio
  102. 6.17.5 CDV Recent Developments
  103. 6.18 Indian Immunologicals
  104. 6.18.1 Indian Immunologicals Company Information
  105. 6.18.2 Indian Immunologicals Business Overview
  106. 6.18.3 Indian Immunologicals Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Indian Immunologicals Anthrax Vaccines Product Portfolio
  108. 6.18.5 Indian Immunologicals Recent Developments
  109. 6.19 Botswana Vaccine Institute
  110. 6.19.1 Botswana Vaccine Institute Company Information
  111. 6.19.2 Botswana Vaccine Institute Business Overview
  112. 6.19.3 Botswana Vaccine Institute Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Botswana Vaccine Institute Anthrax Vaccines Product Portfolio
  114. 6.19.5 Botswana Vaccine Institute Recent Developments
  115. 6.20 Ceva Santé Animale
  116. 6.20.1 Ceva Santé Animale Company Information
  117. 6.20.2 Ceva Santé Animale Business Overview
  118. 6.20.3 Ceva Santé Animale Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Ceva Santé Animale Anthrax Vaccines Product Portfolio
  120. 6.20.5 Ceva Santé Animale Recent Developments
  121. 6.21 Intervac
  122. 6.21.1 Intervac Company Information
  123. 6.21.2 Intervac Business Overview
  124. 6.21.3 Intervac Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Intervac Anthrax Vaccines Product Portfolio
  126. 6.21.5 Intervac Recent Developments
  127. 6.22 JOVAC
  128. 6.22.1 JOVAC Company Information
  129. 6.22.2 JOVAC Business Overview
  130. 6.22.3 JOVAC Anthrax Vaccines Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 JOVAC Anthrax Vaccines Product Portfolio
  132. 6.22.5 JOVAC Recent Developments
7 North America by Country
  1. 7.1 North America Anthrax Vaccines Sales by Country
  2. 7.1.1 North America Anthrax Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Anthrax Vaccines Sales by Country (2021-2026)
  4. 7.1.3 North America Anthrax Vaccines Sales Forecast by Country (2027-2032)
  5. 7.2 North America Anthrax Vaccines Market Size by Country
  6. 7.2.1 North America Anthrax Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Anthrax Vaccines Market Size by Country (2021-2026)
  8. 7.2.3 North America Anthrax Vaccines Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Anthrax Vaccines Sales by Country
  2. 8.1.1 Europe Anthrax Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Anthrax Vaccines Sales by Country (2021-2026)
  4. 8.1.3 Europe Anthrax Vaccines Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Anthrax Vaccines Market Size by Country
  6. 8.2.1 Europe Anthrax Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Anthrax Vaccines Market Size by Country (2021-2026)
  8. 8.2.3 Europe Anthrax Vaccines Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Anthrax Vaccines Sales by Country
  2. 9.1.1 Asia-Pacific Anthrax Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Anthrax Vaccines Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Anthrax Vaccines Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Anthrax Vaccines Market Size by Country
  6. 9.2.1 Asia-Pacific Anthrax Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Anthrax Vaccines Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Anthrax Vaccines Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Anthrax Vaccines Sales by Country
  2. 10.1.1 South America Anthrax Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Anthrax Vaccines Sales by Country (2021-2026)
  4. 10.1.3 South America Anthrax Vaccines Sales Forecast by Country (2027-2032)
  5. 10.2 South America Anthrax Vaccines Market Size by Country
  6. 10.2.1 South America Anthrax Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Anthrax Vaccines Market Size by Country (2021-2026)
  8. 10.2.3 South America Anthrax Vaccines Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Anthrax Vaccines Sales by Country
  2. 11.1.1 Middle East and Africa Anthrax Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Anthrax Vaccines Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Anthrax Vaccines Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Anthrax Vaccines Market Size by Country
  6. 11.2.1 Middle East and Africa Anthrax Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Anthrax Vaccines Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Anthrax Vaccines Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Anthrax Vaccines Value Chain Analysis
  2. 12.1.1 Anthrax Vaccines Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Anthrax Vaccines Production Mode & Process
  7. 12.2 Anthrax Vaccines Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Anthrax Vaccines Distributors
  10. 12.2.3 Anthrax Vaccines Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst